Rhenman & Partners Asset Management Ab Biomarin Pharmaceutical Inc Transaction History

Rhenman & Partners Asset Management Ab

$1.2 Billion
Q3 2024

A detailed history of Rhenman & Partners Asset Management Ab transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 364,500 shares of BMRN stock, worth $23.1 Million. This represents 2.13% of its overall portfolio holdings.

Number of Shares

364,500

Previous 251,500 44.93%

Holding current value

$23.1 Million

Previous $20.7 Million 23.74%

% of portfolio

2.13%

Previous 2.05%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$69.02 - $93.84 $7.8 Million - $10.6 Million	113,000 Added 44.93%	364,500 $25.6 Million
Q2 2024 Aug 13, 2024	BUY	$74.43 - $92.22 $1.04 Million - $1.29 Million	14,000 Added 5.89%	251,500 $20.7 Million
Q1 2024 May 14, 2024	SELL	$83.81 - $99.0 $3.77 Million - $4.46 Million	-45,000 Reduced 15.93%	237,500 $20.7 Million
Q4 2023 Feb 13, 2024	SELL	$76.22 - $98.51 $7.43 Million - $9.6 Million	-97,500 Reduced 25.66%	282,500 $27.2 Million
Q2 2023 Aug 11, 2023	BUY	$86.68 - $100.3 $13.4 Million - $15.5 Million	155,000 Added 68.89%	380,000 $32.9 Million
Q1 2023 May 11, 2023	SELL	$87.74 - $117.27 $2.54 Million - $3.4 Million	-29,000 Reduced 11.42%	225,000 $21.9 Million
Q4 2022 Feb 13, 2023	BUY	$80.93 - $108.63 $1.38 Million - $1.85 Million	17,000 Added 7.17%	254,000 $26.3 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $7.97 Million - $9.4 Million	97,000 Added 69.29%	237,000 $20.5 Million
Q2 2022 Aug 12, 2022	SELL	$71.48 - $86.85 $5.72 Million - $6.95 Million	-80,000 Reduced 36.36%	140,000 $11.6 Million
Q1 2022 May 13, 2022	SELL	$74.28 - $92.69 $3.34 Million - $4.17 Million	-45,000 Reduced 16.98%	220,000 $17 Million
Q4 2021 Feb 11, 2022	BUY	$71.72 - $91.47 $1.79 Million - $2.29 Million	25,000 Added 10.42%	265,000 $23.6 Million
Q3 2021 Nov 12, 2021	BUY	$74.77 - $85.47 $5.98 Million - $6.84 Million	80,000 Added 50.0%	240,000 $18.6 Million
Q2 2021 Aug 13, 2021	SELL	$75.51 - $84.79 $1.51 Million - $1.7 Million	-20,000 Reduced 11.11%	160,000 $13.4 Million
Q1 2021 May 14, 2021	SELL	$74.73 - $90.69 $24.7 Million - $29.9 Million	-330,000 Reduced 64.71%	180,000 $13.6 Million
Q4 2020 Jan 19, 2021	SELL	$72.61 - $90.2 $17 Million - $21.1 Million	-234,354 Reduced 31.48%	510,000 $44.7 Million
Q3 2020 Oct 13, 2020	BUY	$71.87 - $131.03 $39.8 Million - $72.6 Million	554,354 Added 291.77%	744,354 $56.6 Million
Q2 2020 Jul 16, 2020	BUY	$79.55 - $124.22 $410,080 - $640,354	5,155 Added 2.79%	190,000 $23.4 Million
Q1 2020 Apr 16, 2020	SELL	$71.37 - $96.85 $1.8 Million - $2.44 Million	-25,155 Reduced 11.98%	184,845 $15.6 Million
Q4 2019 Jan 17, 2020	SELL	$64.27 - $86.37 $5.17 Million - $6.95 Million	-80,491 Reduced 27.71%	210,000 $17.8 Million
Q3 2019 Oct 16, 2019	BUY	$67.4 - $85.11 $616,170 - $778,075	9,142 Added 3.25%	290,491 $19.6 Million
Q2 2019 Jul 22, 2019	BUY	$80.35 - $93.9 $4 Million - $4.68 Million	49,800 Added 21.51%	281,349 $24.1 Million
Q1 2019 Apr 11, 2019	BUY	$84.2 - $98.62 $4.63 Million - $5.42 Million	55,000 Added 31.15%	231,549 $20.6 Million
Q4 2018 Feb 05, 2019	SELL	$80.14 - $106.07 $7.08 Million - $9.37 Million	-88,300 Reduced 33.34%	176,549 $15 Million
Q3 2018 Oct 03, 2018	BUY	$93.92 - $105.72 $2.35 Million - $2.64 Million	25,000 Added 10.42%	264,849 $25.7 Million
Q2 2018 Jul 20, 2018	BUY	$76.01 - $99.03 $2.66 Million - $3.47 Million	35,000 Added 17.09%	239,849 $22.6 Million
Q1 2018 Apr 11, 2018	BUY	$77.67 - $92.63 $5.05 Million - $6.02 Million	65,000 Added 46.48%	204,849 $16.6 Million
Q4 2017 Jan 19, 2018	SELL	$80.76 - $95.13 $3.24 Million - $3.81 Million	-40,100 Reduced 22.28%	139,849 $12.5 Million
Q3 2017 Oct 13, 2017	BUY	$80.6 - $94.95 $14.5 Million - $17.1 Million	179,949	179,949 $16.7 Million

Others Institutions Holding BMRN

# of Institutions

635

Shares Held

178M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.

Account

Rhenman & Partners Asset Management Ab Biomarin Pharmaceutical Inc Transaction History